Koga, Hironori

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review

Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 509

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration

Fukui, Y., Hashimoto, O., Sanui, T., Oono, T., Koga, H., Abe, M., Inayoshi, A., Noda, M., Oike, M., Shirai, T., et al. (2001) · Nature

Protein Kinase Regulation and GTPase SignalingChemokine receptors and signaling

Cited by 449

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 365

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 333

Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study

Suzuki, A., Mitsuyama, K., Koga, H., Tomiyasu, N., Masuda, J., Takaki, K., Tsuruta, O., Toyonaga, A., & Sata, M. (2006) · Nutrition

Inflammatory Bowel DiseaseProbiotics and Fermented Foods

Cited by 58

Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride‐induced rat liver cirrhotic model

Sakamoto, M., Nakamura, T., Torimura, T., Iwamoto, H., Masuda, H., Koga, H., Abe, M., Hashimoto, O., Ueno, T., & Sata, M. (2013) · Journal of Gastroenterology and Hepatology

Liver Disease and TransplantationLiver physiology and pathology

Cited by 30

Prevention of liver fibrosis and liver reconstitution of DMN‐treated rat liver by transplanted EPCs

Nakamura, T., Torimura, T., Iwamoto, H., Masuda, H., Naitou, M., Koga, H., Abe, M., Hashimoto, O., Tsutsumi, V., Ueno, T., et al. (2012) · European Journal of Clinical Investigation

Liver physiology and pathologyMesenchymal stem cell research

Cited by 27